However, given the paucity of data, our survey results indicate that evaluations are made on a case-by-case basis, often translating practices from head and neck squamous cell carcinomas, by reserving the addition of chemotherapy for young, symptomatic patients with high-volume tumors and high-aggression histology, particularly those with a Ki67 that may predict responsiveness to chemotherapy, in order to counterbalance the burden of toxicities. This evidence concerns the gene MKI67 and head and neck squamous cell carcinoma.